Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30 - Earnings Summary

• Kalvista Pharmaceuticals Inc KALV.OQ reported a quarterly adjusted loss of 99 cents​​ per share for the quarter ended April 30, higher than the same quarter last year, when the company reported EPS of $-1.02. The mean expectation of ten analysts for the quarter was for a loss of 78 cents per share. Wall Street expected results to range from -98 cents to -35 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Kalvista Pharmaceuticals Inc's reported EPS for the quarter was a loss of 99 cents​.

• The company reported a quarterly loss of $52.23 million.

• Kalvista Pharmaceuticals Inc shares had risen by 41.4% this quarter and gained 88.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

This summary was machine generated from LSEG data July 10 at 12:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)